A. Nattermann und Cie. GmbH

Name

A. Nattermann und Cie. GmbH

Legal name

A. Nattermann und Cie. GmbH

Website

https://sanofi-aventis.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Vaccine Cold Chain, Storage & Distribution (HLAIAEAK)

akta.pro secondary industries

Vaccines & Cold-Chain Pharmaceutical Distributors (HLAIAJAG), Vaccine & Public Health Immunization Cold Chain Logistics (TLAIAIAD), Vaccines & Public Health Product Distribution (CRAOAHAI), Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable) (HLAAAEAJ)

Keywords

• Prescription pharmaceuticals
• Vaccines manufacturing
• Consumer healthcare products
• Clinical drug development
• Rare disease therapies

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Prescription Medicines: Revenue generated from patented and off-patent prescription pharmaceutical products across Sanofi's five therapeutic areas: Immunology, Neurology, Oncology, Rare Diseases, and Vaccines.
2. Vaccines: Revenue from vaccine products manufactured and distributed globally through Sanofi's dedicated Vaccines Manufacturing and Supply platform.
3. Consumer Healthcare (Opella): Revenue from consumer healthcare products under the Opella brand, reaching patients directly through over-the-counter and retail channels.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

Core offering

A. Nattermann und Cie. GmbH operates as a German subsidiary within the Sanofi group, contributing to the development, manufacturing, and distribution of pharmaceutical products, vaccines, and consumer healthcare offerings. The parent company's portfolio spans prescription medicines across five therapeutic areas (Immunology, Neurology, Oncology, Rare Diseases, and Vaccines), vaccines through a dedicated manufacturing and supply platform, and consumer healthcare products via the Opella brand.

Differentiator

Problem solved

Functional benefit

Products and services

• Prescription Medicines - Immunology Prescription pharmaceutical products for the treatment of immune-mediated diseases, developed through Sanofi's deep understanding of the immune system. Targeted at healthcare providers and patients with autoimmune conditions.
• Prescription Medicines - Neurology Prescription pharmaceutical products for neurological conditions including CIDP (Chronic Inflammatory Demyelinating Polyneuropathy) and multiple sclerosis. Targeted at healthcare providers and patients with neurological disorders.
• Prescription Medicines - Oncology (Sarclisa) Anticancer treatments including Sarclisa (isatuximab) for multiple myeloma, with subcutaneous formulation approved as first anticancer treatment administered via on-body injector. Targeted at oncologists and patients with cancer.
• Prescription Medicines - Rare Diseases (Nexviazyme) Prescription pharmaceutical products for rare diseases including Nexviazyme (avalglucosidase alfa) for Pompe disease. Targeted at healthcare providers and patients with rare conditions.
• Vaccines Vaccine products manufactured and distributed globally through Sanofi's dedicated Vaccines Manufacturing and Supply platform, covering development, production, and global distribution of vaccine products for preventable diseases.
• Consumer Healthcare (Opella) Consumer healthcare products under the Opella brand, providing over-the-counter medicines and self-care health products reaching consumers globally through retail pharmacies, supermarkets, and over-the-counter channels.

Quantifiable outcome

• 77 compounds in clinical development
• +4 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered minor and core.

• STATION FminorStrategic or Co-development PartnerSanofi x STATION F partnership initiative focused on digital health innovation and startups, providing access to Sanofi's resources and ecosystem at STATION F, the world's largest startup campus.
• OpellacoreStrategic or Co-development PartnerOpella is Sanofi's consumer healthcare business, operating as a dedicated brand portfolio of over-the-counter medicines and health products reaching consumers globally. As Sanofi's consumer health unit, Opella represents a strategic business unit for market expansion in self-care.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Hoechst GmbH: Historic German pharma entity, originally a parent of Nattermann before the Hoechst-Aventis-Sanofi chain of mergers. A relevant comparison for legacy German pharma entities absorbed into the Sanofi group.
• Sanofi-Aventis Deutschland GmbH: Another German operating subsidiary of Sanofi that hosts substantial commercial and manufacturing activity in Germany. Comparable as a sister entity within the same parent group for benchmarking intra-group footprint value.

Broad incumbents

• Pfizer Inc. Global biopharma leader with a major vaccine and biologics portfolio. A peer for vaccines manufacturing scale and distribution complexity relevant to any Sanofi-affiliated German subsidiary.
• Bayer AG (Pharmaceuticals): German pharma major with a substantial pharmaceutical division focused on cardiology, oncology, and women's health. Comparable as a major German pharma peer and a likely competitor for German regulatory and commercial resources.
• Merck KGaA: Major German pharma and life sciences group headquartered in Darmstadt. Comparable as a large-scale German pharma incumbent with diversified pharma and vaccine-adjacent operations.
• Boehringer Ingelheim: Large privately-held German pharmaceutical company with a comparable German-based R&D and manufacturing footprint. Relevant as a peer for benchmarking German pharma entities, especially given Boehringer Ingelheim's own vaccine manufacturing heritage.
• GSK (GlaxoSmithKline): Global biopharma peer with a substantial vaccine franchise, comparable to Sanofi's vaccine platform. Useful for benchmarking vaccines manufacturing, supply, and cold-chain distribution economics.

Regional players

• IDT Biologika GmbH: German CDMO and vaccine manufacturer. Comparable as a German-based vaccines and biologics manufacturer, providing a reference point for the type of economics a reactivated German vaccine subsidiary could pursue.
• Stada Arzneimittel AG: Germany-headquartered specialty pharma company with a strong European generics and consumer health footprint. Comparable as a German pharma entity with consumer healthcare and OTC products, similar to potential consumer health activities moving through the subsidiary.

Emerging players

• BioNTech SE: Germany-based biotech with major vaccine manufacturing operations. Comparable as a German entity operating in vaccine manufacturing and biologics — directly relevant to any future vaccine activity routed through the Nattermann subsidiary.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights4 records

Customer concentration

• Xx.com/sanofi
• YouTubeyoutube.com/sanofi
• Facebookfacebook.com/Sanofi
• LinkedInlinkedin.com/company/a.-nattermann-und-cie.-gmbh
• Instagraminstagram.com/sanofi

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about A. Nattermann und Cie. GmbH